Denice Hickman

800 total citations
9 papers, 223 citations indexed

About

Denice Hickman is a scholar working on Hematology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Denice Hickman has authored 9 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Denice Hickman's work include Acute Myeloid Leukemia Research (5 papers), Histone Deacetylase Inhibitors Research (3 papers) and Multiple Myeloma Research and Treatments (2 papers). Denice Hickman is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Histone Deacetylase Inhibitors Research (3 papers) and Multiple Myeloma Research and Treatments (2 papers). Denice Hickman collaborates with scholars based in United States. Denice Hickman's co-authors include Eyal C. Attar, David A. Sallman, Asmita Mishra, Amy E. DeZern, Michael Byrne, Hugo F. Fernández, Roni Tamari, Yi‐Bin Chen, Mahasweta Gooptu and H. Joachim Deeg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Clinical Pharmacology.

In The Last Decade

Denice Hickman

9 papers receiving 221 citations

Peers

Denice Hickman
Lionel Adès France
Ramy Rahmé France
Jean‐Richard Saint‐Martin United States
Veronica Guerra United States
Edward Ayoub United States
Marta Llop Spain
Stefano Spada Italy
Paul Jäger Germany
Lukas M. Braun Germany
Adele Baker Australia
Lionel Adès France
Denice Hickman
Citations per year, relative to Denice Hickman Denice Hickman (= 1×) peers Lionel Adès

Countries citing papers authored by Denice Hickman

Since Specialization
Citations

This map shows the geographic impact of Denice Hickman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denice Hickman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denice Hickman more than expected).

Fields of papers citing papers by Denice Hickman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denice Hickman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denice Hickman. The network helps show where Denice Hickman may publish in the future.

Co-authorship network of co-authors of Denice Hickman

This figure shows the co-authorship network connecting the top 25 collaborators of Denice Hickman. A scholar is included among the top collaborators of Denice Hickman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denice Hickman. Denice Hickman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Garcia‐Manero, Guillermo, Aaron D. Goldberg, Eric S. Winer, et al.. (2023). Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. The Lancet Haematology. 10(4). e272–e283. 53 indexed citations
2.
DiNardo, Courtney D., Michael R. Savona, Ashwin Kishtagari, et al.. (2023). Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies. Blood. 142(Supplement 1). 4284–4284. 10 indexed citations
3.
4.
Mishra, Asmita, Roni Tamari, Amy E. DeZern, et al.. (2022). Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Clinical Oncology. 40(34). 3985–3993. 98 indexed citations
5.
Dumbrava, Ecaterina E., Amit Mahipal, Xīn Gào, et al.. (2021). Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.. Journal of Clinical Oncology. 39(15_suppl). TPS3161–TPS3161. 3 indexed citations
6.
7.
Garcia‐Manero, Guillermo, Aaron D. Goldberg, Eric S. Winer, et al.. (2021). Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML). Blood. 138(Supplement 1). 3409–3409. 18 indexed citations
8.
9.
Dai, David L., Hua Yang, Salah Nabhan, et al.. (2019). Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. European Journal of Clinical Pharmacology. 75(8). 1099–1108. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lionel Adès Breakdown of academic impact, for papers by Ramy Rahmé Breakdown of academic impact, for papers by Jean‐Richard Saint‐Martin Breakdown of academic impact, for papers by Veronica Guerra Breakdown of academic impact, for papers by Edward Ayoub Breakdown of academic impact, for papers by Marta Llop Breakdown of academic impact, for papers by Stefano Spada Breakdown of academic impact, for papers by Paul Jäger Breakdown of academic impact, for papers by Lukas M. Braun Breakdown of academic impact, for papers by Adele Baker
Rankless by CCL
2026